level-bar

Accelerating Biotech Breakthroughs

Buy tokens
Whitepaper MVP

GENEXI

Token Sale has successfully ended. Thanks to everyone who contributed! Project is in development stage. Stay tuned to our social media channels.

News

Genexi accelerates the transition of cutting-edge biotech projects from research to the market

Token holders

Support the international community to fight counterfeit drugs with digital tools

Future

The development of biotechnology holds tremendous promises for the developing world

Know-how

We pledge to provide regulatory, advisory and research expertise to improve the quality of your life

Help us build the community of biotech and digital health enthusiasts

Genexi
Ecosystem

Transactions via Smart Contracts

  • Efficiency. Eliminate a vast chain of middlemen
  • Speed. No need to process documents manually
  • Security. The highest level of data encryption
  • Trust. Absolute confidence in their execution
  • Transparency. Fully visible T&Cs to all relevant parties

Blockchain Solution for Supply Chain Quality Management

  • Effective fraud detection process
  • Fast access to the supply chain data
  • Full traceability and reduced inherent risks
  • A link between physical and information flows
  • Information sharing between the different stakeholders

Biotech Vendor

  • Focus on the target audience
  • Mitigation of supplier risks
  • Protection of your brand
  • Reduced marketing expenses
  • Increased on-boarding speed
  • Optimised performance

Token GEN

  • Right for specific access to the platform
  • Medium of exchange within the whole ecosystem
  • Reward for your loyalty via bonus programs
  • Transfer of value between distribution chain partners

Global Healthcare Industry Revenue

Growth Rate Forecast: 4.81%

2017 - $1 768 bn.

2018 — $1 853 bn.

Revenue Forecast by Sector

Pharmaceuticals
& Biotechnology

Growth Rate: 4.29%

2017 - $1 195 bn.

2018 — $1 246 bn.

Medical
Technologies

Growth Rate: 5.18%

2017 — $371 bn.

2018 — $390 bn.

In-Vitrio
Diagnostics

Growth Rate: 6.37%

2017 — $108 bn.

2018 — $115 bn.

Healthcare IT

Growth Rate: 9.99%

2017 — $65 bn.

2018 — $72 bn.

Medical Imaging

Growth Rate: 4.42%

2017 — $29 bn.

2018 — $31 bn.

Our Insight

Biotechnology involves transformative technologies for medicine, environment and agriculture. The use of living systems and organisms to make or develop products has increased dramatically over the recent years.

An increasing demand for biotechnology-based diagnostics and therapeutics solutions such as DNA sequencing, tissue engineering and regeneration, cell-based assay promotes funding to support R&D and new product development endeavours.

Growth Opportunities

2017 was a record year for biotech investments. VC funding for digital health accounted for nearly $4.5 billion which is approximately 109% up in comparison with 2016.

According to our estimates, the world biotechnology market value will cross $2 trillion in 2018 with 67% of manufacturers revenue coming from the sales of biotech and pharmaceutical products.

We expect the global biotech industry to register a stable annual growth of around 4.9% during the next 5 years.

Key Biotechnology Areas

DNA Sequencing

Genome analysis cost has significantly reduced because of the emergence of second and third generation sequencing technologies (NGS). As a whole genome scanning cost falls the personalised medicine grows, a new understanding of the genetic variation of individuals is appeared. Moreover, unidentified vast regions of DNA now are clear and unlocked.

Stem Cell Therapy

Medical scientists and drug developers have tremendous opportunities to test drugs in the lab as they see how stem cells are able to grow into any of the body’s specialised cells. However, their major goal and perspective is to rise to an era of regenerative medicine where life-altering injuries and deadly diseases are not just treated, but cured.

Gene Therapy

Commonly, the basic cure for a specific disease is when drugs interact by binding with proteins. Some clinical methods solves this problem by acting directly on genes that are responsible for producing the deleterious protein. For accomplishing this there are number of technologies that introduce a gene through a viral vector, RNAi, antisense or use so-called zinc finger proteins.

MicroRNA

MicroRNA is a new way of diagnosing and treating disease. MicroRNAs prevents the translation of messenger RNA into proteins by breaking down of messenger RNA. The absence or presence of specific microRNAs in various cells is held by specific human diseases, including cancer, viral infection, metabolic disorders and inflammatory disease.

Tissue Engineering

Growing prevalence of chronic diseases heightening the demand for new drug development is one of the key factors of segment growth during the next 5-year period. The combination of biotechnology and pharmaceutical results in the development of effective and advanced therapies used to treat many life threatening diseases.

Implantable Sensors

Intelligent and implantable devices serve medicine with monitoring the health of an individual and, in some cases, alert or even respond to changing conditions within the body.

Vaccine Technology

Biotechnology gives good grounds for expecting cheaper and safer vaccines. Alternatively DNA vaccines use a piece of genetic code for a pathogen instead of using a weakened or killed virus use a piece of genetic code for a pathogen. Traditional methods involve using eggs to grow vaccines. DNA vaccines can be made cardinally quicker and production is more bigger and innovative.

Synthetic Biology

Synthetic biology includes a construction of DNA as a basis for building organisms that can perform specific tasks. It is a major part in developing new biofuels that can break the world’s addiction to petroleum. This sphere draws a great attention for its potential in providing cleaner and renewable sources of fuel. Thus it is changing everything from the way drugs are made to the way industrial goods are manufactured.

Systems Biology

Systems biology focuses on understanding the interaction between a series of genes and their interactions with proteins. Advances in computing, the falling cost of genetic analysis, and other technological advances made this data-intensive approach possible.

Cancer Immuno Therapy

Accelerated breakthroughs in Adoptive T-cell therapies will contribute to the growth of immuno-oncology market during the next 10 years.

Grant Portfolio

Bacteriorhodopsin is a photosensitive protein of purple membranes of Halobacterium salinarum microorganisms living in salt lakes, where the salt concentration is 6 times higher than in the seawater.

Application areas:

Pharmaceutics and cosmetology

Treatment of psoriasis, asthma, conjunctiviti

Agriculture

Plant growth
stimulation

Bioelectronics

Development
of biocomputers

Restet

The RESTET skin regeneration system is the flagship project focused on the research and development of next generation medicines based on bacteriorhodopsin - one of the most promising means of fighting against diseases such as psoriasis, atopic dermatitis, neurodermatitis and acne. RESTET is a unique breakthrough in the field of molecular biocosmetology and has no side effects. The methods of treatment are effective for any age, sex, duration of skin lesions. The unique process of the synthesis of bacteriorhodopsin has been patented in different countries, including Germany, France, China, Iran and South Korea.

ICO

  • Transparency in the use of funds
  • Instant custody without intermediaries
  • Decentralised process of funding technology
  • International reach and flexibility
  • Early contributors will have more liquidity in early stage companies

Genexi Foundation

  • Use blockchain technologies to publish funding and grant information in real time
  • Promote and support Genexi Ecosystem
  • Bring decentralised protocols and digital tools into the biotech field
  • Empower researchers and entrepreneurs to implement their innovative ideas
  • Build a global community of biotech enthusiasts
DistributorsGenexi
Foundation
ManufacturersEcosystemCustomersBlockchainSmart contract

Roadmap

2014

Primary Scientific and Medical Research

Q1 2017

GENEXI Establishment

Q3 2017

Ecosystem and Platform Development

Q1 2018

Low Level Design Launch

Q2 2018

Foundation Establishment

Q3 2018

Fundraising

Q3 2018

Ecosystem Alpha Version Testing

Q4 2018

Smart-Contract Development and Testing. Grant Application Program Launch

H1 2019

Ecosystem Complete Version Launch

H2 2019

Official Public GENEXI Accelerator Report

2020 onwards

Further Ecosystem Development and Scaling

News

13 July 2018

GENEXI Announces Launch of Restet Production

01 July 2018

GENEXI Welcomes Oliver Bussmann To Advisory Board

20 June 2018

London Calling | GENEXI Attends BAIConf 2018

03 June 2018

Meet GENEXI’s New Advisors: Richard O’Rourke & Manuel Rimarachin Dias

22 May 2018

Finwise Summit Tokyo 2018 - GENEXI Insight

18 April 2018

World Blockchain Forum — Investments & ICOs — Dubai

25 March 2018

Global Blockchain Summit Sochi 2018 - A word from our CEO

10 March 2018

Blockchain Leadership Summit | March 9th | Zurich, Switzerland

07 February 2018

GENEXI at Blockchain Economic Forum 2018 in Singapore

14 January 2018

GENEXI - The Finwise Summit Macau 2018

GENEXI Announces Launch of Restet Production

GENEXI Biotech Accelerator has announced the launch of production of their first granted project - RESTET, a skin regeneration system based on the retinal protein bacteriorhodopsin. With the help of grant funds received through GENEXI, the RESTET team was able to build a world-class research lab where they apply their technical know-how to obtain bacteriorhodopsin and produce the RESTET skin regeneration product line. According to GENEXI CEO Aleksei Zheliaskov, RESTET is a unique breakthrough in the field of microbiology and biotechnology, which will become one of the most effective remedies for treatment of skin conditions such as psoriasis, skin dermatitis and acne.

Read the full article

GENEXI Welcomes Oliver Bussmann To Advisory Board

GENEXI Welcomes Oliver Bussmann To Advisory Board June has been another busy and rewarding month for GENEXI with the appointment of new advisors joining GENEXI Foundation. Please welcome a globally recognized technology thought-leader and driver of large-scale transformation at multinational organizations — Oliver Bussmann. The Founder and CEO of Bussmann Advisory AG, Oliver advises enterprises and startups looking to stay ahead of the digital disruption curve. His strengths lie in bringing people together throughout an organization to reach agreement on a desired future state…

Read the full article

London Calling | GENEXI Attends BAIConf 2018

Blockchain Alternative Investment Conference and Exhibition, one of London’s best and most central conference venues, took place on 18–19 June at 8 Northumberland. BAIConf proved to be a resounding success in terms of bringing together the leading fund managers in cryptocurrencies, CEOs of successful ICOs from 2017 and 2018, institutions and private investors responsible for over US$750 billion of assets under management. Global institutional investors conclude for a reason that Bitcoin and other cryptocurrencies are an emerging asset class with real challenges to achieving their full potential…

Read the full article

Meet GENEXI's New Advisors: Richard O'Rourke & Manuel Rimarachin Dias

Often businesses require assistance as they make crucial decisions that affect their direction. Experienced advisors can bring the insight business owners need. June 2018, GENEXI is proud to announce new advisors joining the team: Richard O'Rourke and Manuel Rimarachin Dias. GENEXI’s culture is a standout in the world of business and marketing planning, rewarding forward thinking and creativity. Our advisors are our greatest success – we say it often and with good reason. The company instils confidence in our employees and their external teammates, always inspiring one another to find a way forward and master their motivation. We foster a culture of innovation and leadership bringing in the right people to continue develop those values further.

Read the full article

Finwise Summit Tokyo 2018 - GENEXI Insight

2018 FINWISE Tokyo was held in Tokyo Japan on May 21-22. FINWISE Summit is one of the most influential blockchain events in the world which aims to strengthen the communication among blockchain- related practitioners and encourage the development of global financial technologies. GENEXI Ecosystem Developer Dennis Sarkar was invited as a speaker to announce GENEXI blockchain platform and fundraising campaign that promotes the culture of innovations, as well as embedding the blockchain into biotechnology.

Read the full article

World Blockchain Forum — Investments & ICOs — Dubai

The World Blockchain Forum, Investment & ICOs was held on 16 -17 April, 2018 in Dubai. Major market players joined the leaders of several countries, economic pioneers and enterprising investors hailing from all corners of the world in discussing the future of the financial world. According to GENEXI co-founder and CEO Alexey Zhelyaskov, one of the conference's primary objectives was to understand the strategic tasks of blockchain globalization within the context of rapidly changing economic conditions.

Read the full article

CEO on blockchain and the real sector at the Global Blockchain Summit 2018 in Sochi

Sochi played host to the Global Blockchain Summit 2018, an international event dedicated to blockchain technology and cryptocurrencies, on 24 March. The program included reports on the following set of pressing issues: the use of blockchain and its future, ICOs, altcoin prospects in 2018 and infrastructural challenges. GENEXI co-founder and CEO Alexey Zhelyaskov delivered a speech on the integration of blockchain and the real sector of economy.

Read the full article

Blockchain Leadership Summit | March 9th | Zurich, Switzerland

The Blockchain Leadership Summit took place on 9 March, 2018 in Zurich, Switzerland. It is widely regarded as one of the main conferences for experts and visionaries of the blockchain industry. Experts from the real sector, pioneers of the digital economy, investment bankers and officials from Switzerland, Liechtenstein, Kazakhstan, and Russia were among the attendees.

Read the full article

GENEXI at Blockchain Economic Forum 2018 in Singapore

GENEXI co-founder and CEO Alexey Zhelyaskov attended the Blockchain Economic Forum, held on 4-6 February, 2018 in Singapore. The Blockchain Economic Forum accentuated the growing influence of the crypto economy on global economic processes and facilitated a productive dialogue on the most crucial topics. The presence of Vincente Fox, the former President of Mexico, should be noted.

Read the full article

GENEXI took part in the FINWISE SUMMIT 2018 in Macau

The Finwise Summit was held on 12-13 January, 2018 in Macau. It was aimed at encouraging interaction among the fintech industry participants and fostering further developments in this field. Over 3000 guests, hundreds of investment and fintech companies and roughly 60 blockchain projects attended the summit. UBS and a number of large Chinese banks were listed as major partners.

Read the full article

Join Genexi

Success

We will contact you soon

Partners

Press about us